concern. While macrolide AMR is increasing globally, ESC AMR is low and extensive drug-resistance (XDR) rare.

**Methods** We report the clinical management and microbiology of two recent cases of XDR NG in the UK.

**Results** Case A (female) presented to a sexual health clinic (SHC) in October 2018 with urinary symptoms. She cleared the infection following treatment with ceftriaxone 500 mg plus azithromycin 1g. She had recently had vaginal intercourse with ≥1 male partner in Ibiza, Spain. Case B (female) presented to a SHC elsewhere in England in November 2018 with anal and genital symptoms. She had recently had unprotected vaginal, oral and anal sex with an asymptomatic man who had been in Ibiza and had links with the same sexual network as case A. He tested NG NAAT-negative in December without treatment. Case B initially responded clinically to treatment with ceftriaxone 1g, but symptoms relapsed and she remained culture-positive 2 weeks later. She failed subsequent treatment with gentamicin 240 mg plus azithromycin 2g but cleared the infection with 3 days of IV ertapenem. Both isolates were resistant to ceftriaxone (MIC 1.0 mg/L), cefixime, penicillin, ciprofloxacin and tetracycline, had intermediate susceptibility to azithromycin (MIC 0.5 mg/L), and were susceptible to spectinomycin. Whole genome sequencing indicated that both isolates were from the FC428 clone, which has been reported sporadically globally, usually with epidemiological links to the Asia-Pacific region.

**Conclusion** These FC428 clone isolates are able to cause both asymptomatic and symptomatic infection with a variable response to ceftriaxone and azithromycin treatment. This clone is likely to increase over time in Europe and threatens the effectiveness of gonorrhoea treatment. Surveillance of AMR, test-of-cure, extra-genital sampling and partner notification are vital to maintain effective treatment and prevent spread.

**Disclosure** No significant relationships.

---

**P676 AZITHROMYCIN RESISTANCE AMONG NEISSERIA GONORRHOEAE CASES IN KING COUNTY, WASHINGTON, USA, 2017–2018**

1Christina Thibault*, 2Olusegun Soge, 3Lindsey Barbee, 1Roxanne Kerani, 1Dawn Spellman, 1Sarah Stewart, 1Anna Harrington, 2Rusliene Pascual, 1Matthew Golden, 1Public Health – Seattle and King County, HIV/STD Program, Seattle, USA; 2University of Washington, Global Health, Seattle, USA; 3University of Washington, Medicine, Seattle, USA

10.1136/sextrans-2019-sti.742

**Background** Public Health – Seattle & King County (PHSKC) participates in Strengthening the U.S. Response to Resistant Gonorrhea (SURRG), funded by the Centers for Disease Control and Prevention, to enhance surveillance of antimicrobial resistance in Neisseria gonorrhoeae (GC). We aimed to identify predictors of azithromycin-resistant GC.

**Methods** GC culture specimens were collected from patients with GC infection who attended the PHSKC STD Clinic or one of five King County, Washington, medical clinics during 2017–2018. Positive culture isolates underwent azithromycin Etest susceptibility testing with Etest; azithromycin resistance (AZI-R) was defined as minimum inhibitory concentration ≥2.0 μg/mL. Clinical and sociobehavioral data was obtained from medical records and partner services interviews; we compared characteristics of cases with and without AZI-R and evaluated statistical significance with chi-square and Fisher’s exact tests.

**Results** During 2017–2018, 1,164 GC isolates from 1,048 unique cases underwent azithromycin Etest susceptibility testing. Overall, 6.5% of isolates and 6.8% of cases had AZI-R. Prevalence was higher in rectal isolates (8.3% of 373) than urethral (5.0% of 496, p=0.05) and similar to pharyngeal (7.4% of 270, p=0.68). AZI-R was more common in men who have sex with men ( MSM ) than heterosexuals (8% vs 3%, p=0.04), and in Hispanics vs. non-Hispanics (12% vs 6%, p<0.01). Age, GC history, number of sex partners, HIV-status, PrEP-status, and diagnosing facility type were not associated with AZI-R. Most (95%) AZI-R cases were treated with an azithromycin-containing regimen (dual therapy with ceftriaxone (92%) or gentamicin (4%)). Nearly all (96%) had a documented negative test of cure (culture and/or NAAT); no treatment failures were observed.

**Conclusion** AZI-R was identified in 6.8% of GC cases in King County, Washington. While more common in MSM and Hispanic persons, AZI-R was not strongly associated with other characteristics we evaluated. Health care providers should be aware of the potential for AZI-R in patients with GC.

**Disclosure** No significant relationships.